New mRNA vaccine trial targets HIV-Linked cancers
NCT ID NCT07563023
First seen May 05, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This early-phase study tests an mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV-related lymphoma. The vaccine aims to help the immune system fight cancer cells that are driven by EBV. The trial will enroll 6 adults and primarily check for safety and immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV ASSOCIATED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.